Eleftherios Alexandrou, MD
Ophthalmology · Woonsocket, RINPI 1912168352
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $165 and has fallen 56.2% since, to $72 in 2025. That places this record below the midpoint for ophthalmology clinicians in RI, where the typical reported total is $781.
Across 37 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$121
- Sun Pharmaceutical Industries Inc.$121
- Bausch & Lomb, A Division Of Bausch Health US, LLC$105
- Novartis$103
- Bausch & Lomb Americas Inc.$75
- Kala Pharmaceuticals, Inc.$50
- plus $154 from 6 others
What the payments were for
- Food & beverage$731100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 6 | $121 |
| Sun Pharmaceutical Industries Inc. | 6 | $121 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $105 |
| Novartis | 5 | $103 |
| Bausch & Lomb Americas Inc. | 4 | $75 |
| Kala Pharmaceuticals, Inc. | 3 | $50 |
| Rayner Intraocular Lenses Limited | 2 | $35 |
| AbbVie(2 entities) | 2 | $34 |
| Oyster Point Pharma, Inc. | 1 | $33 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
| Biotissue Holdings Inc. | 1 | $17 |
| Harrow Eye, LLC | 1 | $17 |
How this compares
$731 in reported general payments places this provider in the 45th percentile of 69 ophthalmology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlevroNepafenac | 136 | $52,600 |
| LumiganBimatoprost | 99 | $37,820 |
| Bromfenac Sodium | 151 | $37,120 |
| Lotemax SmLoteprednol Etabonate | 131 | $33,326 |
| Prednisolone Acetate | 436 | $23,933 |
| ProlensaBromfenac Sodium | 63 | $21,856 |
| Difluprednate | 223 | $19,572 |
| XiidraLifitegrast | 25 | $16,923 |
| Ketorolac Tromethamine | 419 | $10,676 |
| Ofloxacin | 827 | $9,708 |
| Brimonidine Tartrate | 63 | $952 |
| Latanoprost | 94 | $950 |
| ErythromycinErythromycin Base | 27 | $333 |
| Acyclovir | 28 | $284 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 15 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa | $105 | $55,181194 claims |
| NovartisIlevro | $103 | $52,600136 claims |
| AbbVieLumigan | $34 | $37,82099 claims |
| Bausch & Lomb Americas Inc.Xiidra | $75 | $16,92325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 69 ophthalmology providers in Rhode Island.
Other ophthalmology in Woonsocket
- Sarah AnisProvidence$163K
- Sarah LevyWakefield$148K
- Nermin GraiseWarwick$60K
- Jesse RichmanProvidence$30K
- Alex GerberMiddletown$15K
- Yoash EnzerProvidence$11K
- Giulio DiamanteJohnston$6K
- David TienProvidence$6K
- Leah KammerdienerWarwick$6K
- Nikolas RaufiJohnston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.